The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients
Abstract
Boosted protease inhibitor regimens combine ritonavir with a second, 'boosted' protease inhibitor to enhance patient exposure to the latter agent, thereby preventing or overcoming resistance and allowing less frequent dosing, potentially improving adherence. The advantages offered by ritonavir boosting are primarily attributable to the drug's pharmacokinetic properties. Ritonavir's inhibition of the cytochrome P-450 CYP3A4 enzyme reduces the metabolism of concomitantly administered protease inhibitors and changes their pharmacokinetic parameters, including area under the curve (AUC), maximum concentration (Cmax), minimum concentration (Cmin) and half-life (t1/2). As a result, the bioavailability of the boosted protease inhibitor is increased and improved penetration into HIV reservoirs may be achieved. Boosted protease inhibitor regimens that utilize a low dose of ritonavir (100-200 mg) appear to offer the best balance of efficacy and tolerability. At this dose, ritonavir boosts the bioavailability of the second protease inhibitor without contributing significantly to the side effect profile of the regimen. In clinical trials, regimens boosted with low dose ritonavir have demonstrated high levels of viral suppression in both antiretroviral naïve patients and patients who previously failed antiretroviral therapy, including protease inhibitor therapy. Side effects observed have generally been similar to those associated with the boosted protease inhibitor. Based upon their enhanced drug exposure and demonstrated efficacy, the boosted ritonavir regimens should be among the first options considered for use in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-2-199907200-00002 · Cited by 843
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341602 · Cited by 745
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Tsiodras, S., Mantzoros, C., Hammer, S., & Samore, M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.13.2050 · Cited by 452
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
Fromm, M. F. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38069 · Cited by 399
Saves, M., Raffi, F., Capeau, J., Rozenbaum, W., Ragnaud, J., Perronne, C., Basdevant, A., Leport, C., Chene, G., & the Antiproteases Cohorte (APROCO) Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/339866 · Cited by 254
Murphy, R. L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A. C., Benson, C., Thompson, M., Kessler, H. A., et al. (2001) · AIDS · doi:10.1097/00002030-200101050-00002 · Cited by 238
Huisman, M. T., Smit, J. W., Crommentuyn, K. M., Zelcer, N., Wiltshire, H. R., Beijnen, J. H., & Schinkel, A. H. (2002) · AIDS · doi:10.1097/00002030-200211220-00009 · Cited by 222
Drewe, J., Gutmann, H., Fricker, G., Török, M., Beglinger, C., & Huwyler, J. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00026-x · Cited by 183
Interactions of HIV Protease Inhibitors with ATP-Dependent Drug Export Proteins
Gutmann, H., Fricker, G., Drewe, J., Toeroek, M., & Miller, D. S. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12649-1 · Cited by 180
Cited by
A Comprehensive Review About SARS-CoV-2
Haque, S. M., Ashwaq, O., Sarief, A., & Azad John Mohamed, A. K. (2020) · Future Virology · doi:10.2217/fvl-2020-0124 · Cited by 121
Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86
COVID-19 Treatment: The Race Against Time
Aljofan, M., & Gaipov, A. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/7890 · Cited by 27
Song, Y., Schroeder, J. R., & Bush, L. M. (2014) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/2325957413488187 · Cited by 22
Metadata
- Authors
- Zeldin, R. K.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-04
- Volume
- 53
- Issue
- 1
- Pages
- 4-9
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2164349191
- Cited by
- 316
- References
- 20
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. https://app.cochat.ai/papers/10.1093/jac/dkh029
- The paper
- Zeldin, R. K. (2003). Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkh029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
